EKSO BIONICS HOLDINGS Business Summary

Ekso Bionics Holdings, Inc. (EKSO) operates a dual-track business model centered on the design and sale of wearable robotic exoskeleton systems, generating revenue through direct capital equipment sales, multi-year service and maintenance contracts, and strategic distribution partnerships. The company is organized into two primary segments: EksoHealth, which provides FDA-cleared rehabilitation solutions like the EksoNR and Indego Therapy for patients with spinal cord injuries, stroke, and multiple sclerosis; and EksoWorks, which offers industrial upper-body devices such as the Ekso EVO to mitigate worker fatigue and repetitive strain. In early 2026, the company significantly expanded its total addressable market by securing CMS reimbursement for its Indego Personal device and entering a non-binding merger agreement with Applied Digital to form ChronoScale Corporation, a venture targeting AI workloads. EKSO competes directly with Lifeward (formerly ReWalk Robotics), Cyberdyne, Ottobock, and Sarcos Robotics, maintaining a market-leading position through its extensive patent portfolio and first-mover advantage in clinical neurorehabilitation. Founded in 2005 by Homayoon Kazerooni, Russ Angold, and Nathan Harding out of the University of California, Berkeley’s Robotics and Human Engineering Laboratory, the company is led by a veteran executive team with deep technical and operational pedigree. CEO Scott Davis, appointed in 2022, brings over two decades of experience from high-tech and IoT firms including Sierra Wireless and Globalmatix. He is supported by CFO Jerome Wong, a former Deloitte audit manager who has overseen the company’s financial strategy since 2017, and COO Jason Jones, a UC Berkeley-trained engineer with a background in medical device development and industrial automation. The company’s governance is bolstered by a board featuring Lead Independent Director Mary Ann Cloyd (formerly a senior partner at PwC) and Dr. Corinna Lathan (founder of AnthroTronix). Notable institutional backing includes positions held by Citadel Advisors, Vanguard Group, and Geode Capital Management, alongside a $5.9 million private placement secured in January 2026 to fund ongoing commercial scaling.